Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
about
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitisImmunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center CohortTNFα inhibitor induced lupus-like syndrome (TAILS) in a patient with IBD.Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.Recent advances and current state of immunotherapy in systemic lupus erythematosus.Tumour necrosis factor antagonist-induced lupus: a Critically Appraised Topic.Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.Unusual and Interesting Adverse Cutaneous Drug Reactions.Management Decisions for Rheumatoid Arthritis After Tumor Necrosis Factor Alpha Antagonist-Induced Lupus-Like Syndrome
P2860
Q26774173-C7D06DF1-ECBD-43D3-BC84-40ADF634E220Q28554222-D7DC622D-80AA-4F03-9230-0E06A0D69A59Q36453770-F98E6219-6FB4-483C-A575-C25D31192304Q37599165-8A856630-B5F6-4D32-90C3-F7144D2AE6FBQ38445319-EDADA093-0CA1-48AF-8642-BFB49E6375DCQ38757680-203BFA50-3539-4851-9D60-231E45218FFEQ38794663-B0987120-BDCE-43EC-A281-C7B98BC2DF05Q48298265-CCCF3149-D4E1-4AB3-ACF8-87C94D7CB41EQ50083992-B35D118C-4E92-4A67-8C80-58957839A5BBQ55099672-1F774C7D-6441-4416-A171-F0184D063A27Q58134824-2E2F16F6-AE40-4886-A20D-BE4744E80FAF
P2860
Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Is the risk of tumour necrosis ...... de pharmacovigilance database.
@en
Is the risk of tumour necrosis ...... de pharmacovigilance database.
@nl
type
label
Is the risk of tumour necrosis ...... de pharmacovigilance database.
@en
Is the risk of tumour necrosis ...... de pharmacovigilance database.
@nl
prefLabel
Is the risk of tumour necrosis ...... de pharmacovigilance database.
@en
Is the risk of tumour necrosis ...... de pharmacovigilance database.
@nl
P2093
P2860
P921
P356
P1433
P1476
Is the risk of tumour necrosis ...... de pharmacovigilance database.
@en
P2093
Agnès Sommet
Association Française des Centres Régionaux de PharmacoVigilance
Guillaume Moulis
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEU214
P577
2014-06-04T00:00:00Z